4-(6-chloropyridin-3-yloxy)quinazoline | 1134120-44-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(6-chloropyridin-3-yloxy)quinazoline
• 英文别名: 4-(6-chloropyridin-3-yl)oxyquinazoline
• CAS: 1134120-44-7
• 化学式: C₁₃H₈ClN₃O
• 分子量: 257.679
• InChiKey: GTESEEZCPWYKGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  47.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yloxy)quinazoline 、 2-氯-5-吡啶硼酸 在 四(三苯基膦)钯 、 氧气 、 caesium carbonate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 10.0h， 以74%的产率得到4-(6-chloropyridin-3-yloxy)quinazoline
  参考文献：
  名称：

  Wacharasindhu, Sumrit; Bardhan, Sujata; Wan, Zhao-Kui, Journal of the American Chemical Society, 2009, vol. 131, p. 4174 - 4175

  摘要：

  DOI：

文献信息

• HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION
  申请人：Mansour Tarek Suhayl

  公开号：US20090291971A1

  公开（公告）日：2009-11-26

  The present invention relates to processes for the preparation of heteroaryl ethers. In some embodiments, the processes relate to cross coupling reactions between triazol-1-yloxy and triazol-1-yl heterocycles with aryl boronic acids. In a further aspect, this invention also relates to compounds that are useful for the treatment of oncological diseases or disorders, and for the treatment of inflammation.

  本发明涉及制备杂环基醚的过程。在某些实施例中，该过程涉及三唑-1-氧基和三唑-1-基杂环与芳基硼酸之间的交叉偶联反应。在进一步的方面，本发明还涉及用于治疗肿瘤疾病或障碍以及治疗炎症的化合物。
• INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Nerviano Medical Sciences S.r.l.

  公开号：EP2120932A1

  公开（公告）日：2009-11-25
• COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS
  申请人：Ignyta, Inc.

  公开号：EP3107541A1

  公开（公告）日：2016-12-28
• [EN] INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE L'INDAZOLE EN TANT QU'INHIBITEURS DES KINASES POUR LE TRAITEMENT DU CANCER
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2008074749A1

  公开（公告）日：2008-06-26

  [EN] Substituted indazole derivativesof formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a dysregulated protein kinase activity, like cancer. formula (I)
  [FR] La présente invention concerne des dérivés d'indazole substitués de formule (I) et leurs sels pharmaceutiquement acceptables, tels que définis dans le mémoire descriptif, leur procédé de préparation et des compositions pharmaceutiques qui les comprennent. Les composés selon l'invention ont une utilisation thérapeutique pour le traitement de maladies associée à une activité protéine-kinase déréglée telles que le cancer. Formule (I)
• [EN] HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION<br/>[FR] HÉTÉROARYL ÉTHERS ET LEURS PROCÉDÉS DE PRÉPARATION
  申请人：WYETH CORP

  公开号：WO2009058937A2

  公开（公告）日：2009-05-07

  The present invention relates to processes for the preparation of of heteroaryl ethers. In some embodiments, the processes relate to cross coupling reactions between triazol-1-yloxy and triazol-1-yl heterocycles with aryl boronic acids. In a further aspect, this invention also relates to compounds that are useful for the treatment of oncological diseases or disorders, and for the treatment of inflammation.